Trial · NCT00817531

Efficacy Study of Dasatinib in Locally Advanced Triple-Negative Breast Cancer Patients

NCT00817531, Phase 2, Terminated, Baylor Breast Care Center; results first posted 2012-07-17

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Efficacy Study of Dasatinib in Locally Advanced Triple-Negative Breast Cancer Patients. Trials, record NCT00817531. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00817531

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Efficacy Study of Dasatinib in Locally Advanced Triple-Negative Breast Cancer Patients
NCT number: NCT00817531
Status: Terminated
Phases: Phase 2
Enrollment: 22 participants, actual
Lead sponsor: Baylor Breast Care Center
Conditions: Breast Cancer
Interventions: Dasatinib
First posted: 2009-01-06
Last updated: 2012-08-31
Results first posted: 2012-07-17
Limitations and caveats: The study was terminated after internal analysis due to treatment futility. It does not meet the required number of responses to continue the study.

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Clinical Efficacy	Assessment at pre-surgery or 3 to 4 weeks of treatment.	The clinical response was assessed using RECIST and based on the changes in the longest diameter of the target lesion measured. Complete Response (CR), Disappearance of the target lesion; Partial Response (PR), \>=30% decrease in the diameter of target lesion compared to baseline; Progressive disease (PD), \>= 20% increase in the diameter of target lession, taking as reference the smallest diameter recorded since the baseline measurement or the appearance of new lesion; Stable disease (SD), neither sufficient shrinkage as PR or sufficient increase as PD.

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Clinical Efficacy	Assessment at pre-surgery or 3 to 4 weeks of treatment.	All patients started the treatment will be included in the analysis	participants	NUMBER

Source ClinicalTrials.gov

Results by group3

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Units
Clinical Efficacy	Dasatinib	Partial Response (PR)	2	participants
Clinical Efficacy	Dasatinib	Stable Disease (SD)	15	participants
Clinical Efficacy	Dasatinib	Progression Disease (PD)	5	participants

Source ClinicalTrials.gov

Participant flow3

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Dasatinib	22
Overall Study	COMPLETED	Dasatinib	20
Overall Study	NOT COMPLETED	Dasatinib	2

Source ClinicalTrials.gov

Adverse events16

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	ALT, SGPT(serum glutamic pyruvic transaminase)	Metabolism and nutrition disorders	Dasatinib	9	22	10
other	AST, SGOT(serum glutamic oxaloacetic transaminase)	Metabolism and nutrition disorders	Dasatinib	11	22	12
other	Albumin, serum-low (hypoalbuminemia)	Metabolism and nutrition disorders	Dasatinib	2	22	2
other	Calcium, serum-low (hypocalcemia)	Metabolism and nutrition disorders	Dasatinib	7	22	7
other	Constipation	Gastrointestinal disorders	Dasatinib	2	22	2
other	Diarrhea	Gastrointestinal disorders	Dasatinib	3	22	3
other	Fatigue (asthenia, lethargy, malaise)	General disorders	Dasatinib	4	22	4
other	Glucose, serum-high (hyperglycemia)	Metabolism and nutrition disorders	Dasatinib	5	22	5
other	Hemoglobin	Blood and lymphatic system disorders	Dasatinib	6	22	6
other	Infection	Infections and infestations	Dasatinib	3	22	4

1 to 10 of 16Source ClinicalTrials.gov

See all 16 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Dasatinib
Total, other adverse events	Dasatinib	22	22
Total, serious adverse events	Dasatinib	1	22

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00817531

GET https://conductscience.org/api/trials/v1/NCT00817531/registered

API reference For AI assistants